You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. sxRNA-based Antiviral Approach targeting Epstein-Barr virus

    SBC: HocusLocus Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this Phase I is to develop a prototype for a novel antiviral therapy directed towards Epstein Barr virus based on a novel post transcriptional regulatory mechanism called structurally interacting RNA or sxRNA We are pioneering a revolutionary antiviral approach that uses a viral encoded microRNA miRNA to create specificity even in infections in t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Picture Me Fit: Engaging Youth in Community-Based Prevention

    SBC: PREVENTION STRATEGIES, LLC            Topic: 600

    DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    DESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Technology-Guided Opioid Cessation for Post-Operative Pain

    SBC: MedicaSafe Inc            Topic: R41

    DESCRIPTION provided by applicant This STTR application proposes development of MedicaSafe Inc andapos s Multimodal Analgesic Protection System MAPSafe Built around MedicaSafeandapos s proprietary Medication Therapy Optimization MTO technology MAPSafe will be designed to mitigate the myriad risks associated with prescription opioid use post operatively and throughout recovery after surge ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides

    SBC: Initos Pharmaceuticals LLC            Topic: 999

    DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Real-Time Spliced-RNA Detection to Quantify Latent HIV-Infected Cells in HAART Patients

    SBC: JAN BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The CDC estimates that in the U S people aged years and older are living with HIV infection with approximately others infected but undiagnosed CDC Strict adherence to highly active combination anti retroviral therapy HAART cART prevents full blown AIDS However HAART cART fails to cure HIV infection as it has little ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Developing therapeutic inhibitors of CIB1 for breast cancer

    SBC: Reveris Therapeutics            Topic: 102

    DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an Antigen Capture Assay for Babesia microti

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government